Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Progenics Pharmaceuticals Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio is managed by 1 distinct examiner and 1 distinct art unit. AMANDA L AGUIRRE is the busiest examiner, with 1 pending office action. The prosecution is currently focused on a single examiner within one art unit.
The data indicates 1 pending office action, which is the only active matter for the company. This action is classified under the Biotechnology & Pharmaceuticals technology area. AMANDA L AGUIRRE is the sole examiner assigned to the portfolio, and she works within 1 distinct art unit. This shows a highly concentrated prosecution landscape with no diversification across different examiners or art units.
For a practitioner, the success of the current prosecution depends entirely on AMANDA L AGUIRRE. With 1 distinct examiner and 1 distinct art unit, there are no other pending cases to provide a broader perspective on how the company's biotechnology is being evaluated. The outcome of this 1 pending office action will be the primary measure of the company's current patent office success. The alignment of the total pending actions with a single examiner and art unit indicates a singular focus for the current prosecution cycle.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGUIRRE, AMANDA L | 1 | 77.2% | +15.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18744219 | SYNTHESIS OF THE PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) RADIOLABELED INHIBITOR [18F]DCFPYL | AGUIRRE, AMANDA L | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18744219 | SYNTHESIS OF THE PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) RADIOLABELED INHIBITOR [18F]DCFPYL | AGUIRRE, AMANDA L | 1626 | §103 | Final Rejection | — | Pending | Jun 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial